Mon premier blog

Pharmacokinetic-pharmacodynamic modeling and simulation Peter L Bonate, SpringerLink
Publisher: Springer

Title:Pharmacokinetic-Pharmacodynamic Modeling and Simulation Author:Peter L. 2006 Pharmacokinetic-Pharmacodynamic Modeling and Simulation, . And Pharmacodynamics of Abused Drugs, CRC Press, Boca Raton, FL ISBN 978-1-4200-5458-3; Kimko, H. Bonate Publisher:Springer ISBN:139939399X ISBN33: Date3116-31-31. Results (preliminary): The Aarons L, Kyle DE, White NJ. Quantitative representation of the dose-concentration- response relationship should provide PK-PD simulations allow the assessment of the descriptive parameters as the functions of dose and dose rate. Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments. 2004 Pharmacokinetics in Drug Development: Regulatory and Development Paradigms, Volume 2, AAPS Press, Arlington, VA ISBN 0-9711767-3-6; Bonate, P.L. This finding provides motivation for conducting more pharmacokinetic-pharmacodynamic (PK-PD) studies of artesunate to monitor its effectiveness and re-assess current dosing regimens. Designing these studies is The derived optimal designs were then evaluated via a simulation-estimation procedure. Learn How to Build Automated Traffic Machines. Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance. A comprehensive simulation study to assess the utility of a stage-specific pharmacokinetic-pharmacodynamic (PK-PD) model for predicting within-host parasite response was performed. Pharmacokinetic-Pharmacodynamic Modeling and Simulation By Peter Bonate Publisher: Springer Number Of Pages: 387. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Pharmacokinetic-pharmacodynamic (PK-PD) modeling has emerged as a major tool in clinical pharmacology to optimize drug use by designing rational dosage forms and dosage regimes. Joomi Lee, MS; Yangha Hwang Financial disclosure: This research was supported by the Korea National Enterprise for Clinical Trials, a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, the Republic of South Korea (A070001), and by the Pfizer Modeling & Simulation Education Center in Korea (PMECK). By providing this infrastructure Devidas believes the partners can maximise the usefulness of pharmacokinetic/pharmacodynamic modeling and simulation (M&S) and increase its value in the drug development process. Population Pharmacokinetic/Pharmacodynamic Modeling of Clopidogrel in Korean Healthy Volunteers and Stroke Patients.